IL153375A0 - Agonist anti-trk-c monoclonal antibodies - Google Patents
Agonist anti-trk-c monoclonal antibodiesInfo
- Publication number
- IL153375A0 IL153375A0 IL15337501A IL15337501A IL153375A0 IL 153375 A0 IL153375 A0 IL 153375A0 IL 15337501 A IL15337501 A IL 15337501A IL 15337501 A IL15337501 A IL 15337501A IL 153375 A0 IL153375 A0 IL 153375A0
- Authority
- IL
- Israel
- Prior art keywords
- monoclonal antibodies
- agonist anti
- trk
- trkc
- antibodies
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 2
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000005779 cell damage Effects 0.000 abstract 1
- 208000037887 cell injury Diseases 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000003278 mimic effect Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000047459 trkC Receptor Human genes 0.000 abstract 1
- 108010064892 trkC Receptor Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21314100P | 2000-06-22 | 2000-06-22 | |
US23831900P | 2000-10-05 | 2000-10-05 | |
PCT/US2001/020153 WO2001098361A2 (fr) | 2000-06-22 | 2001-06-22 | Anticorps monoclonaux anti-trk-c agonistes |
Publications (1)
Publication Number | Publication Date |
---|---|
IL153375A0 true IL153375A0 (en) | 2003-07-06 |
Family
ID=26907807
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15337501A IL153375A0 (en) | 2000-06-22 | 2001-06-22 | Agonist anti-trk-c monoclonal antibodies |
IL153375A IL153375A (en) | 2000-06-22 | 2002-12-11 | Monoclonal antibodies to the anti-C-TRK agonist |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL153375A IL153375A (en) | 2000-06-22 | 2002-12-11 | Monoclonal antibodies to the anti-C-TRK agonist |
Country Status (17)
Country | Link |
---|---|
US (4) | US7384632B2 (fr) |
EP (1) | EP1292680B1 (fr) |
JP (1) | JP2004500873A (fr) |
KR (1) | KR100823764B1 (fr) |
CN (1) | CN100519749C (fr) |
AT (1) | ATE446366T1 (fr) |
AU (2) | AU2001271422B2 (fr) |
BR (1) | BR0112272A (fr) |
CA (1) | CA2412494C (fr) |
DE (1) | DE60140252D1 (fr) |
DK (1) | DK1292680T3 (fr) |
HU (1) | HU228310B1 (fr) |
IL (2) | IL153375A0 (fr) |
MX (1) | MXPA02012602A (fr) |
NZ (1) | NZ523105A (fr) |
PL (1) | PL208113B1 (fr) |
WO (1) | WO2001098361A2 (fr) |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5877016A (en) * | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
EP3333182A1 (fr) | 2000-06-05 | 2018-06-13 | The Brigham and Women's Hospital, Inc. | Gène encodant un homologue p-glycoprotéine humain multi-résistant aux médicaments pour le chromosome 7p15-21 et utilisations associées |
DE60140252D1 (de) * | 2000-06-22 | 2009-12-03 | Genentech Inc | Agonistische monoklonale antikörper gegen trkc |
GB0210783D0 (en) * | 2002-05-10 | 2002-06-19 | Polonelli Luciano | Anti-microbial polypeptides |
WO2004044584A1 (fr) * | 2002-11-13 | 2004-05-27 | Micromet Ag | Procede d'identification de cellules b specifiques d'un antigene |
EP1581759B1 (fr) * | 2002-12-23 | 2009-05-13 | Rinat Neuroscience Corp. | Methodes de traitement de la neuropathie sensorielle induite par le taxol |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
JP2006520806A (ja) * | 2003-03-20 | 2006-09-14 | ライナット ニューロサイエンス コーポレイション | タキソール誘導性腸障害を処置する方法 |
KR20070001932A (ko) * | 2003-12-23 | 2007-01-04 | 리나트 뉴로사이언스 코퍼레이션 | 작용물질 항 티알케이씨 항체 및 그의 사용 방법 |
AR054260A1 (es) * | 2005-04-26 | 2007-06-13 | Rinat Neuroscience Corp | Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos |
MX2007015292A (es) * | 2005-06-06 | 2008-02-21 | Wyeth Corp | Anticuerpos monoclonales anti-trkb y sus usos. |
CN103145842A (zh) * | 2005-06-30 | 2013-06-12 | Abbvie公司 | Il-12/p40结合蛋白 |
PT2289909E (pt) | 2005-11-30 | 2015-02-10 | Abbvie Inc | Método de rastreio, processo de purificação de globulómeros a-beta não difundíveis, anticorpos selectivos contra os referidos globulómeros a-beta não difundíveis e processo para o fabrico dos referidos anticorpos |
KR20140087058A (ko) | 2005-11-30 | 2014-07-08 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
JP2009528985A (ja) | 2006-02-02 | 2009-08-13 | ライナット ニューロサイエンス コーポレイション | trkBアゴニストを投与することにより望まれない体重減少または摂食障害を治療する方法 |
PL2772535T3 (pl) | 2006-05-31 | 2022-09-05 | Children's Medical Center Corporation | Mezenchymalne komórki macierzyste ABC5 dodatnie jako immunomodulatory |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
US8648169B2 (en) * | 2006-12-05 | 2014-02-11 | The Royal Institution For The Advancement Of Learning/Mcgill University | Methods of use of Trk receptor modulators |
IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses. |
US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
JP5889527B2 (ja) | 2007-04-12 | 2016-03-22 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. | 癌療法のためのabcb5標的化 |
EP2262837A4 (fr) * | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Protéines de liaison avec pd-1 |
JP5758289B2 (ja) * | 2008-05-21 | 2015-08-05 | サントル、ナショナール、ド、ラ、ルシェルシュ、シアンティフィク、(セーエヌエルエス) | NT−3:TrkC結合の阻害および神経芽腫などの癌の処置へのその適用 |
RS53350B (en) | 2008-09-22 | 2014-10-31 | Array Biopharma, Inc. | SUBSTITUTED COMPOUNDS OF IMIDASO [1,2-B] PYRIDASINE AS INK KINASE INHIBITORS |
SG10201914059WA (en) | 2008-10-22 | 2020-03-30 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
WO2010056332A1 (fr) | 2008-11-14 | 2010-05-20 | The Brigham And Women's Hospital, Inc. | Méthodes diagnostiques et thérapeutiques se rapportant à des cellules souches cancéreuses |
US11542328B2 (en) | 2008-11-14 | 2023-01-03 | The Brigham And Women's Hospital, Inc. | Therapeutic and diagnostic methods relating to cancer stem cells |
MX2011006422A (es) | 2008-12-19 | 2011-09-15 | Panima Pharmaceuticals Ag | Autoanticuerpos humanos anti-alfa-sinucleina. |
EP2421900A1 (fr) | 2009-04-24 | 2012-02-29 | Alper Biotech, Llc | Anticorps monoclonaux dirigés contre des antigènes pcbp-1 et leurs utilisations |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
EP2473531A4 (fr) | 2009-09-03 | 2013-05-01 | Merck Sharp & Dohme | Anticorps anti-gitr |
ES2684475T3 (es) | 2010-04-15 | 2018-10-03 | Abbvie Inc. | Proteínas que se unen a beta amiloide |
SG10201506591TA (en) | 2010-05-20 | 2015-09-29 | Array Biopharma Inc | Macrocyclic compounds as trk kinase inhibitors |
KR20130048240A (ko) | 2010-07-14 | 2013-05-09 | 알퍼 바이오테크, 엘엘씨 | Pcbp―1 항원에 대한 모노클로날 항체, 및 그의 용도 |
MX358739B (es) | 2010-08-14 | 2018-09-03 | Abbvie Inc Star | Proteinas de union a amiloide beta. |
US9200080B2 (en) | 2010-09-03 | 2015-12-01 | Horacio Uri Saragovi | Agonistic antibodies to TrkC receptors and uses thereof |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
MX359070B (es) | 2010-12-01 | 2018-09-13 | Alderbio Holdings Llc | Composiciones anti-ngf y uso de las mismas. |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
EP4086338A1 (fr) * | 2011-03-17 | 2022-11-09 | Minerva Biotechnologies Corporation | Procédé d'obtention de cellules souches pluripotentes |
EA030777B9 (ru) | 2011-06-23 | 2019-02-28 | Байоджен Интернэшнл Нейросайенз Гмбх | Анти-альфа-синуклеинсвязывающие молекулы |
AU2012279288B2 (en) * | 2011-07-01 | 2017-07-20 | The Trustees Of The University Of Pennsylvania | Anti-properdin antibodies and uses thereof |
RU2635289C2 (ru) * | 2012-05-09 | 2017-11-09 | Конинклейке Филипс Н.В. | Медицинский интерфейс слежения, обеспечивающий интервенционную информацию |
AU2013326932B2 (en) | 2012-10-04 | 2019-06-06 | Novelmed Therapeutics, Inc. | Alternative pathway specific antibodies for treating hemolytic diseases |
CN107428760B (zh) | 2014-11-16 | 2021-04-27 | 阵列生物制药公司 | (s)-n-(5-((r)-2-(2,5-二氟苯基)-吡咯烷-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羟基吡咯烷-1-甲酰胺硫酸氢盐的晶型 |
MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
JP2018526324A (ja) | 2015-06-01 | 2018-09-13 | ロクソ オンコロジー, インコーポレイテッドLoxo Oncology, Inc. | がんの診断および処置の方法 |
WO2016193872A2 (fr) | 2015-06-05 | 2016-12-08 | Novartis Ag | Anticorps ciblant la protéine morphogénétique osseuse 9 (bmp9) et méthodes associées |
CA2992586A1 (fr) | 2015-07-16 | 2017-01-19 | Array Biopharma, Inc. | Composes substitues de pyrazolo[1,5-a]pyridines comme inhibiteurs de la kinase ret |
KR20180037994A (ko) | 2015-07-28 | 2018-04-13 | 오토노미, 인코포레이티드 | TrkB 또는 TrkC 아고니스트 조성물 및 귀 병태의 치료 방법 |
CA3003153A1 (fr) | 2015-10-26 | 2017-05-04 | Loxo Oncology, Inc. | Mutations ponctuelles dans le cancer resistant aux inhibiteurs de trk et methodes associees |
PL3370768T3 (pl) | 2015-11-03 | 2022-06-13 | Janssen Biotech, Inc. | Przeciwciała specyficznie wiążące pd-1 i ich zastosowania |
TW201736399A (zh) | 2015-12-31 | 2017-10-16 | 財團法人生物技術開發中心 | 抗vegfr抗體及其應用 |
AU2017246547B2 (en) | 2016-04-04 | 2023-02-23 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
UA125026C2 (uk) | 2016-04-04 | 2021-12-29 | Локсо Онколоджі, Інк. | РІДКІ КОМПОЗИЦІЇ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)ПІРАЗОЛО[1,5-a]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
UA127826C2 (uk) | 2016-05-18 | 2024-01-17 | Локсо Онколоджі, Інк. | СПОСІБ ОДЕРЖАННЯ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)-ПІРАЗОЛО[1,5-а]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ |
CA3029281A1 (fr) | 2016-06-29 | 2018-01-04 | Otonomy, Inc. | Formulations otiques a base de triglycerides et leurs utilisations |
TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
RU2766582C2 (ru) | 2016-12-23 | 2022-03-15 | Ремд Биотерапьютикс, Инк. | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) |
US11168090B2 (en) | 2017-01-18 | 2021-11-09 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors |
WO2018136663A1 (fr) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Inhibiteurs de ret |
WO2018166495A1 (fr) * | 2017-03-15 | 2018-09-20 | Tsinghua University | Nouveaux anticorps anti-trkb |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
JP2020525470A (ja) * | 2017-07-03 | 2020-08-27 | ディヴェロップメント センター フォー バイオテクノロジー | 抗vegfr抗体及びその使用 |
IL272773B2 (en) | 2017-08-22 | 2024-06-01 | Biogen Ma Inc | Pharmaceutical preparations containing anti-amyloid cell antibodies |
US11786551B2 (en) | 2017-09-26 | 2023-10-17 | The Trustees Of The University Of Pennsylvania | Methods for treating heart disease via redirected T cell immunotherapies |
TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
EP3695003A4 (fr) * | 2017-10-13 | 2021-12-22 | Adimab, LLC | Anticorps contre le virus respiratoire syncytial et méthodes pour leurs génération et utilisation |
EP3700576A1 (fr) | 2017-10-26 | 2020-09-02 | Array Biopharma Inc. | Formulations d'un inhibiteur de kinase trk macrocyclique |
JP7061195B2 (ja) | 2018-01-18 | 2022-04-27 | アレイ バイオファーマ インコーポレイテッド | RETキナーゼ阻害剤としての置換ピラゾロ[3,4-d]ピリミジン化合物 |
CN111615514B (zh) | 2018-01-18 | 2022-10-11 | 奥瑞生物药品公司 | 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物 |
WO2019143977A1 (fr) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Composés de pyrrolo[2,3-d]pyrimidines substitués utilisés en tant qu'inhibiteurs de la kinase ret |
US20210023086A1 (en) | 2018-03-29 | 2021-01-28 | Loxo Oncology, Inc. | Treatment of trk-associated cancers |
CA3108065A1 (fr) | 2018-07-31 | 2020-02-06 | Loxo Oncology, Inc. | Dispersions sechees par pulverisation, formulations et polymorphies de (s)-5-amino-3-(4-((5 fluoro-2-methoxybenzamido)methyl)phenyl)(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide |
ES2922314T3 (es) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Compuestos heterocíclicos condensados como inhibidores de cinasa RET |
JP2022515197A (ja) | 2018-12-19 | 2022-02-17 | アレイ バイオファーマ インコーポレイテッド | がんを治療するためのfgfr阻害剤としての7-((3,5-ジメトキシフェニル)アミノ)キノキサリン誘導体 |
EP3898626A1 (fr) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | Composés pyrazolo[1,5-a]pyridine substitués servant d'inhibiteurs de tyrosine kinases fgfr |
US20210087295A1 (en) * | 2019-09-23 | 2021-03-25 | The Trustees Of The University Of Pennsylvania | Disrupting tumor tissues by targeting fibroblast activation protein (fap) |
CN117447602B (zh) * | 2023-12-22 | 2024-03-19 | 北京索莱宝科技有限公司 | 猪IgM的抗体及其应用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
CA2040099A1 (fr) | 1990-05-01 | 1991-11-02 | Mariano Barbacid | Tyrosine-kinase-negative trkb |
US5364769A (en) * | 1990-09-25 | 1994-11-15 | Genentech, Inc. | Nucleic acid encoding neurotrophic factor four (NT-4), vectors, host cells and methods of production |
US5348856A (en) * | 1991-07-08 | 1994-09-20 | E. R. Squibb & Sons, Inc. | DNA encoding TRKC protein |
EP0573904B1 (fr) * | 1992-06-08 | 2001-09-26 | Takeda Chemical Industries, Ltd. | Agent thérapeutique pour neutropénie |
US5855885A (en) * | 1993-01-22 | 1999-01-05 | Smith; Rodger | Isolation and production of catalytic antibodies using phage technology |
US5659791A (en) * | 1993-04-26 | 1997-08-19 | Microsoft Corporation | Encapsulation of extracted portions of documents into objects |
WO1995014776A1 (fr) * | 1993-11-23 | 1995-06-01 | Genentech, Inc. | TYROSINE KINASES PROTEIQUES APPELEES Rse |
ES2116066T3 (es) | 1993-11-23 | 1998-07-01 | Genentech Inc | Ensayo de activacion del receptor quinasa. |
US5753225A (en) * | 1993-12-03 | 1998-05-19 | The Regents Of The University Of California | Antibodies that mimic actions of neurotrophins |
US5877016A (en) * | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
JPH07285912A (ja) * | 1994-04-19 | 1995-10-31 | Asahi Chem Ind Co Ltd | 新規化合物am5221 |
WO1996036361A1 (fr) * | 1995-05-18 | 1996-11-21 | The Regents Of The University Of Michigan | Anticorps se fixant a un adn |
AU690474B2 (en) * | 1995-09-11 | 1998-04-23 | Kyowa Hakko Kirin Co., Ltd. | Antibody againts alpha-chain of human interleukin 5 receptor |
GB9525180D0 (en) | 1995-12-08 | 1996-02-07 | Univ Mcgill | Design of hormone-like antibodies with agonistic and antagonistic fuctions |
JP2001527402A (ja) | 1997-04-25 | 2001-12-25 | ジェネンテック,インコーポレーテッド | Ngf変異体 |
ATE406907T1 (de) | 1998-10-28 | 2008-09-15 | Cornell Res Foundation Inc | Methoden zur regulierung der angiogenese und vaskuläre integrität mittels trk rezeptor liganden bdnf, nt-3 und nt-4 |
US6656474B1 (en) * | 1999-01-15 | 2003-12-02 | Regeneron Pharmaceuticals, Inc. | Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders |
DE60140252D1 (de) * | 2000-06-22 | 2009-12-03 | Genentech Inc | Agonistische monoklonale antikörper gegen trkc |
-
2001
- 2001-06-22 DE DE60140252T patent/DE60140252D1/de not_active Expired - Lifetime
- 2001-06-22 JP JP2002504316A patent/JP2004500873A/ja active Pending
- 2001-06-22 AT AT01950429T patent/ATE446366T1/de not_active IP Right Cessation
- 2001-06-22 PL PL359926A patent/PL208113B1/pl unknown
- 2001-06-22 NZ NZ523105A patent/NZ523105A/en not_active IP Right Cessation
- 2001-06-22 US US10/312,316 patent/US7384632B2/en not_active Expired - Lifetime
- 2001-06-22 AU AU2001271422A patent/AU2001271422B2/en not_active Ceased
- 2001-06-22 CA CA2412494A patent/CA2412494C/fr not_active Expired - Lifetime
- 2001-06-22 WO PCT/US2001/020153 patent/WO2001098361A2/fr active IP Right Grant
- 2001-06-22 CN CNB018144217A patent/CN100519749C/zh not_active Expired - Lifetime
- 2001-06-22 EP EP01950429A patent/EP1292680B1/fr not_active Expired - Lifetime
- 2001-06-22 BR BR0112272-0A patent/BR0112272A/pt not_active IP Right Cessation
- 2001-06-22 MX MXPA02012602A patent/MXPA02012602A/es active IP Right Grant
- 2001-06-22 KR KR1020027017506A patent/KR100823764B1/ko active IP Right Grant
- 2001-06-22 IL IL15337501A patent/IL153375A0/xx unknown
- 2001-06-22 DK DK01950429.9T patent/DK1292680T3/da active
- 2001-06-22 HU HU0300841A patent/HU228310B1/hu unknown
- 2001-06-22 AU AU7142201A patent/AU7142201A/xx active Pending
-
2002
- 2002-12-11 IL IL153375A patent/IL153375A/en active IP Right Grant
-
2006
- 2006-10-16 US US11/581,865 patent/US7615383B2/en not_active Expired - Lifetime
-
2009
- 2009-06-04 US US12/478,501 patent/US20100003261A1/en not_active Abandoned
-
2011
- 2011-08-05 US US13/198,979 patent/US20120045443A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE60140252D1 (de) | 2009-12-03 |
US20040137513A1 (en) | 2004-07-15 |
AU2001271422B2 (en) | 2005-12-22 |
MXPA02012602A (es) | 2003-05-14 |
IL153375A (en) | 2009-06-15 |
US7615383B2 (en) | 2009-11-10 |
US20120045443A1 (en) | 2012-02-23 |
US20070036794A1 (en) | 2007-02-15 |
AU7142201A (en) | 2002-01-02 |
PL359926A1 (en) | 2004-09-06 |
HUP0300841A3 (en) | 2005-11-28 |
HUP0300841A2 (hu) | 2004-06-28 |
ATE446366T1 (de) | 2009-11-15 |
WO2001098361A2 (fr) | 2001-12-27 |
US7384632B2 (en) | 2008-06-10 |
NZ523105A (en) | 2004-07-30 |
KR20030036240A (ko) | 2003-05-09 |
EP1292680A2 (fr) | 2003-03-19 |
WO2001098361A9 (fr) | 2003-03-06 |
CA2412494A1 (fr) | 2001-12-27 |
EP1292680B1 (fr) | 2009-10-21 |
CN100519749C (zh) | 2009-07-29 |
BR0112272A (pt) | 2003-05-06 |
US20100003261A1 (en) | 2010-01-07 |
DK1292680T3 (da) | 2010-03-08 |
CA2412494C (fr) | 2012-10-23 |
CN1447857A (zh) | 2003-10-08 |
PL208113B1 (pl) | 2011-03-31 |
HU228310B1 (en) | 2013-03-28 |
KR100823764B1 (ko) | 2008-04-21 |
JP2004500873A (ja) | 2004-01-15 |
WO2001098361A3 (fr) | 2002-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU7142201A (en) | Agonist anti-trk-c monoclonal antibodies | |
MXPA02000119A (es) | Elementos mezcladores estaticos apilados. | |
MX2008007502A (es) | Anticuerpos anti mn y metodos para su utilizacion. | |
TW200635608A (en) | Aβ antibodies for use in improving cognition | |
TW200635607A (en) | Humanized Aβ antibodies for use in improving cognition | |
DE69435307D1 (de) | Bazillus Thuringiensis und dessen insektizide Proteine | |
WO2002069900A3 (fr) | Procede de traitement de troubles proliferatifs d'origine genetique par des inhibiteurs de hsp90 | |
NI200800032A (es) | Reducción de célula b utilizando moléculas de unión específicas cd37 y cd20 | |
YU9404A (sh) | Multimerna, usmerena kontrastna sredstva na bazi peptida | |
WO2006063152A3 (fr) | Combinaisons et procedes d'immunostimulation | |
SG158141A1 (en) | Pancreatic polypeptide family motifs, polypeptides and methods comprising the same | |
WO2004034990A3 (fr) | Methodes et compositions a utiliser dans le traitement du cancer | |
EP1700120A4 (fr) | Marqueur pour la neuromyelite optique | |
HK1069767A1 (en) | Methods for inhibiting ocular processes | |
TNSN06202A1 (en) | Anticorps agonistes inti-trkc et procedes qui les utilisent | |
BRPI0508084A (pt) | método para o tratamento de um distúrbio neurológico, e, uso de meridamicina ou um sal do mesmo | |
MX2007002227A (es) | Composicion y metodo para ablandar carne. | |
PL346246A1 (en) | Modulating multiple lineage kinase proteins | |
DE602006018461D1 (de) | Galk1s als modifikatoren des pten/akt-wegs | |
WO2004083241A3 (fr) | Proteines interagissant avec btc et utilisation de ces proteines | |
WO2005101013A3 (fr) | Substances et procedes pour le criblage de modulateurs de la regeneration neuronale | |
PL338678A1 (en) | Derivatives of 4-cyano-4-deformylsordacin | |
NZ514691A (en) | Method to type prion proteins | |
ATE528392T1 (de) | Neues protein und dessen dns | |
Bowal | Freedom of Conscience and Religion |